Sage Therapeutics Inc (NAS:SAGE)
$ 11.09 0.46 (4.31%) Market Cap: 667.42 Mil Enterprise Value: -72.17 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 46/100

SAGE Therapeutics Inc at Piper Sandler Healthcare Conference (Virtual) Transcript

Dec 01, 2021 / 01:30PM GMT
Release Date Price: $37.15 (-4.52%)
Yasmeen Rahimi
Piper Sandler & Co., Research Division - Director & Senior Research Analyst

Thank you for joining our live fireside chat during our Piper Sandler Conference. My name is Yas Rahimi. I'm a senior biotech analyst here at Piper Sandler. I am so thrilled to be featuring Sage Therapeutics. Joining me on Zoom is Barry Greene, CEO. We have quite a bit to cover in the next 30 minutes.

And first, I'm going to start off on congratulating you on two great announcements this morning. One is the data set -- the 12 months data set from SHORELINE across the 50-milligram dose group. And the second one is the unveiling of the design of the SAGE-718 Phase II DIMENSION study. For investors who may have missed that new information, it is available on the website -- of Sage's website, and we'll talk about that.

Questions & Answers

Yasmeen Rahimi
Piper Sandler & Co., Research Division - Director & Senior Research Analyst

But let's kick off the discussion with the new data that's just off of the press, the 12-month SHORELINE data

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot